Fig. 1: Hybrid immunity induces higher serum SARS-CoV-2 binding and neutralizing antibody titers then vaccination alone. | npj Vaccines

Fig. 1: Hybrid immunity induces higher serum SARS-CoV-2 binding and neutralizing antibody titers then vaccination alone.

From: SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity

Fig. 1

a Longitudinal serum spike (S)-specific IgG titers of SARS-CoV-2 variants in vaccinees without (white box), and with prior COVID-19 (hybrids, grey box) sampled before, and 28 days and 6 months after vaccination. Groups are color-coded similar to panels b and c. b S-specific IgG titers to SARS-CoV-2 variants in hybrid immune controls (green), chronic kidney disease patients (CKD, yellow), patients on dialysis (blue) and kidney transplant recipients (KTR, red). The 50% effective concentration serum S-specific IgG titers were determined by ELISA. c) The serum antibody titers of a 50% plaque reduction neutralization test (PRNT50) using clinical virus isolates of each variant. Symbols, central line, box and whiskers represent individual patients, the mean, interquartile range and minimum or maximum values, respectively. Horizontal dotted lines indicate the upper (ULoD) and lower limits of detection (LLoD). Significant differences calculated by Mann–Whitney-U test are indicated (***p < 0.005 and ****p < 0.001).

Back to article page